[HTML][HTML] Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with …
…, P Velazco-Villares, JP Bacallao-Castillo… - The Lancet Regional …, 2023 - thelancet.com
Background SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated
to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting …
to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting …
[HTML][HTML] Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination
…, RGM Romero, OS Tabio, PMV Villares, JPB Castillo… - MedRxiv, 2021 - medrxiv.org
Background SOBERANA 02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated
to tetanus toxoid). Phase 1 and 2 clinical trials demonstrated its high immunogenicity, …
to tetanus toxoid). Phase 1 and 2 clinical trials demonstrated its high immunogenicity, …
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA …
…, P Velazco-Villares, JP Bacallao-Castillo… - MedRxiv, 2022 - medrxiv.org
Background SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated
to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting …
to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting …
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA …
…, P Velazco-Villares, JP Bacallao-Castillo… - 2021 - europepmc.org
Background SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated
to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting …
to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting …
[PDF][PDF] Methods for measuring health inequalities (Part III)
MC Schneider, C Castillo-Salgado, J Bacallao… - Epidemiol Bull, 2005 - iris.paho.org
The health variable used in the examples is the infant mortality rate (IMR) per 1,000 live births
(LB), obtained from PAHO’s basic indicators for 1997. 6 The other demographic indicators …
(LB), obtained from PAHO’s basic indicators for 1997. 6 The other demographic indicators …
Trends in infant mortality inequalities in the Americas: 1955–1995
…, E Loyola-Elizondo, J Bacallao… - … of Epidemiology & …, 2002 - jech.bmj.com
Study objectives: To describe overall and income related trends in infant mortality
inequalities in the Region of the Americas from 1955 to 1995. Design: Infant mortality rates (IMRs) …
inequalities in the Region of the Americas from 1955 to 1995. Design: Infant mortality rates (IMRs) …
[PDF][PDF] Future incidence scenarios of the Ischemic Heart Disease: a dynamic predictive simulation model.
…, J de Jesús Mejía-Saavedra, JP Castillo-Palencia… - researchgate.net
Purpose. To develop a dynamic holistic predictive model to generate future scenarios of the
ischemic heart disease. Methodology: Nine indicators were analyzed at municipality level by …
ischemic heart disease. Methodology: Nine indicators were analyzed at municipality level by …
Acculturative stress and depressive symptomatology among Mexican and Mexican American students in the US: Examining associations with cultural incongruity and …
This study examined associations of intragroup marginalization and cultural incongruity with
acculturative stress and depressive symptoms among 155 undergraduate US college …
acculturative stress and depressive symptoms among 155 undergraduate US college …
Fear vs. facts: Examining the economic impact of undocumented immigrants in the US
Undocumented immigration has become a contentious issue in the US over the past decade.
Opponents of undocumented immigration have argued that undocumented immigrants are …
Opponents of undocumented immigration have argued that undocumented immigrants are …
[CITATION][C] SOBERANA Phase 3 team. 2023. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous …
…, P Velazco-Villares, JP Bacallao-Castillo… - 2022